Fast Track vs Breakthrough Therapy vs RMAT vs Priority Review vs National Priority Voucher

FDA expedited programs in practice: Fast Track, Breakthrough Therapy, RMAT, Priority Review, and the Commissioner's National Priority Voucher

The short answer

The four statutory expedited programs do different jobs. None of them lowers the approval standard.

• Fast Track gives you access: more frequent meetings and eligibility for rolling review ²⁸⁴¹.
• Breakthrough Therapy designation (BTD) adds intensive FDA involvement early in development, backed by an organizational commitment that includes senior managers ⁴².
• RMAT designation gives regenerative medicine products all the BTD features on a lower evidentiary trigger. It also points more explicitly toward accelerated approval ⁸⁵²⁹⁴⁷.
• Priority Review is a separate step. It shortens the review clock from 10 months to 6 months, and FDA assigns it at filing ^31269271.

The Commissioner's National Priority Voucher (CNPV) pilot is newer, and FDA created it without a dedicated statute. It targets an action 1 to 2 months after the final submission. It gets there by front-loading CMC and labeling review and by running a team-based "tumor board" review ⁷⁷⁷⁵⁷⁸. Early CNPV approvals have come in roughly 44 to 50 days after filing ^5960416. The program has also produced at least one complete response ⁵⁹, and critics have questioned its legal basis and how products are selected ³²⁷³³¹.

Side-by-side comparison

Fast Track: access, not acceleration by itself

The core guidance is still Expedited Programs for Serious Conditions: Drugs and Biologics (May 2014) ⁴⁸. What Fast Track actually gives you is more interaction with FDA. That includes pre-IND, end-of-phase 1, and end-of-phase 2 meetings covering study design, the safety database, dose-response, and biomarkers ²⁸. The second benefit is rolling review. If FDA's preliminary look at the clinical data suggests the product may be effective, FDA can start reviewing parts of the marketing application before the complete application arrives ⁴¹.

Two limits matter in practice:

• Fast Track does not include priority review. It only makes the product eligible if the data at submission support it ²⁸.
• Accelerated approval is a separate pathway. FDA may discuss it with the sponsor during Fast Track interactions, but designation does not confer it ²⁸³¹.

FDA can rescind the designation if emerging data no longer support the unmet-need showing, or if the sponsor stops pursuing the designated program ³¹³⁸.

Scale. CBER data from March 1998 through January 31, 2024 show 814 Fast Track requests, 581 granted and 218 denied ¹⁰⁶. Among CDER novel approvals, 22 of 50 in 2024 (44%) had Fast Track ¹⁰⁸, as did 18 of 46 in 2025 (39%) ¹⁰⁹.

Breakthrough Therapy: how much FDA engages

BTD carries a higher bar. Sponsors need clinical evidence of a treatment effect that may be a substantial improvement over available therapy, generally from phase 1 or phase 2 trials. Mechanistic or nonclinical data alone are not enough ³¹⁹. A clinically significant endpoint can be:

• irreversible morbidity or mortality, or serious symptoms,
• an established surrogate endpoint,
• a surrogate reasonably likely to predict benefit, or
• a clearly better safety profile with similar efficacy ³¹³³¹⁴.

BTD adds to Fast Track in three ways:

• intensive, interactive guidance from as early as phase 1, including discussion of adaptive, enrichment, crossover, or historically controlled designs ^3144229;
• intensive involvement of senior managers and experienced review staff ⁴²;
• a cross-disciplinary project lead where appropriate ⁴².

The benefit is front-loaded. FDA wants requests before the efficacy trials start, and it rarely sees them after a marketing application has been submitted ³⁸³¹.

BTD can be lost. If another drug gets traditional approval for the same use, the designated product generally keeps BTD only if it may still show substantial improvement over that newly approved drug. FDA gives the sponsor notice and a chance to argue for keeping the designation, and rescission does not rule out eventual approval ⁴¹³²¹.

Precedents from Drugs@FDA review files. These records show BTD, Fast Track, rolling review, and priority review used together:

• Cabometyx (cabozantinib), NDA 208692. Fast Track was granted April 8, 2015, and BTD August 21, 2015. The rolling NDA began October 13, 2015, and the final clinical component was submitted December 22, 2015. The application was reviewed as Priority and has a decision date of April 25, 2016, about four months after the last component went in ²⁹⁶²⁹⁷.
• Adakveo (crizanlizumab-tmca), BLA 761128. BTD was granted December 20, 2018, and rolling review February 7, 2019. The last of six BLA submissions arrived May 16, 2019. The Priority review ended in a decision on November 15, 2019 ²⁹³.
• Imbruvica (ibrutinib), NDA 205552. Fast Track was granted October 2012 and BTD March 2013. FDA granted rolling review April 18, 2013, and the three NDA parts arrived April 25, May 31, and June 28, 2013. The record is Priority. The June 2013 NDA covered two indications and was administratively split: mantle-cell lymphoma (Original 1) was approved November 13, 2013, and CLL (Original 2) on February 12, 2014. The cited review ³⁰⁴ is the Original 2 (CLL) review.
• Praxbind (idarucizumab), BLA 761025. This BTD product had its rolling BLA completed February 20, 2015. The Priority review ended in a decision on October 16, 2015 ²⁹⁸.

The review files cited here do not state PDUFA goal dates, so they cannot show how these approvals compared with their goals. Cumulatively, CDER reports 337 breakthrough therapy approvals as of December 31, 2025 ¹¹¹. In calendar 2025, 15 of CDER's 46 novel approvals had BTD ¹⁰⁹.

RMAT: breakthrough-level engagement for regenerative medicine

RMAT guidance is in Expedited Programs for Regenerative Medicine Therapies for Serious Conditions (February 2019) ⁹⁰. The main difference from BTD is the evidentiary trigger. RMAT requires preliminary clinical evidence of potential to address an unmet medical need. It does not require evidence of substantial improvement over available therapy ⁸⁵⁸⁴.

CBER will also accept a wider range of preliminary evidence:

• appropriately chosen historical controls,
• well-designed retrospective studies,
• case series with systematically collected data, and
• studies conducted outside the United States ⁴⁷.

Once designated, an RMAT product gets every BTD feature (and so every Fast Track feature) ²⁹. It also gets early interactions on surrogate or intermediate endpoints that could support accelerated approval ⁴⁷²⁹. The statute also directs attention to ways of supporting accelerated approval and meeting postapproval requirements ²⁹. Like BTD, RMAT is not an approval and does not change the safety and effectiveness standard ⁸⁴.

Precedents. Through FY2025 (September 30, 2025), FDA received 388 RMAT requests and granted 193 ⁶⁴. It lists 14 approved products that held RMAT designation, including Casgevy, Zevaskyn, Aucatzyl, Tecelra, Lenmeldy, Amtagvi, Roctavian, and Breyanzi ⁷¹. Two regulatory histories show how RMAT combines with other programs:

• Casgevy (exagamglogene autotemcel). RMAT was granted May 5, 2020, alongside Fast Track, Orphan, and Priority Review. The BLA arrived April 3, 2023, was filed June 8, 2023, and was approved December 8, 2023 ³⁷⁸. That is six months after filing, in line with the priority goal for original BLAs, which runs from the 60-day filing date ²⁶⁹.
• Otarmeni (lunsotogene parvec-cwha). RMAT was granted July 5, 2024. The product also held Fast Track, Orphan, Priority Review, and accelerated approval, and it was reviewed under the CNPV pilot. The complete BLA arrived December 23, 2025, was filed with priority review February 21, 2026, and was approved April 23, 2026 ³⁸⁰.

Priority Review: the only program that changes the review clock

Priority review changes how long FDA takes to act. It does not change the approval pathway or the evidence needed. Under the PDUFA goals, FDA aims to act on 90% of applications within these windows ²⁶⁹:

"Act" means issuing either an approval or a complete response letter. Meeting the goal does not mean approval ²⁶⁹. FDA decides priority status case by case at filing and tells the applicant by day 60 ^26831271.

The clock can move. Palynziq (pegvaliase-pqpz), BLA 761079 was received June 30, 2017 under priority review. A major amendment then extended the review by three months, to a PDUFA goal of May 28, 2018. FDA acted May 24, 2018 ³⁵¹.

How often priority review is used. Drugs@FDA approval-letter records for original applications classified as new molecular entities show this split (example records: ^{115116117118119120121122}):

These are counts of original applications, not products, so a product approved under two applications (lenacapavir in 2025, for example) counts twice and yearly totals can exceed CDER's novel-approval counts.

The designations stack. A product with Fast Track or BTD commonly also gets priority review at filing, as the Cabometyx, Adakveo, and Casgevy records show ^296293378.

Where accelerated approval fits

Accelerated approval is an approval pathway, not a designation. It lets FDA approve on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, for a serious condition where the product offers a meaningful advantage over available therapy ¹⁰⁵⁷. The statutory standards stay the same, and confirmatory trials must verify the benefit ³¹⁰.

Congress tightened the pathway in section 3210 of the Consolidated Appropriations Act, 2023 ²²⁵¹. FDA's draft guidances from December 2024 and January 2025 cover the resulting changes:

• FDA generally intends to require confirmatory trials to be underway before approval, and may require enrollment to be complete in some cases ³⁶⁹¹².
• Sponsors must submit progress reports roughly every 180 days ¹².
• FDA can use expedited withdrawal procedures if a trial is not run with due diligence or fails to confirm benefit ^370372373.

This affects BTD and RMAT planning. The early discussions on surrogate endpoints that those designations support now need to cover confirmatory trial readiness too.

Commissioner's National Priority Voucher: a different kind of acceleration

Mechanics

FDA announced the CNPV pilot on June 17, 2025 ⁷⁷. It covers CDER, CBER, and the Oncology Center of Excellence ⁷⁵⁷⁸. The target is an action within 1 to 2 months after the final application is submitted, compared with roughly 10 to 12 months for a standard review ⁷⁷⁷⁴⁷⁶.

The program saves time by removing idle periods. It does not reduce the amount of review:

• Pre-submission. CMC and draft labeling are due at least 60 days before the final submission, and other modules follow an agreed schedule ⁷⁷⁷⁵.
• Ongoing communication. Sponsors are expected to answer FDA questions quickly. Early engagement is meant to catch CMC, inspection, and labeling problems before they extend the review ⁷⁷⁷⁶⁸³.
• Tumor-board review. The center's review team still does the independent scientific review. It then presents its findings to a multidisciplinary CNPV Review Council at a one-day meeting. The Council's recommendations are non-binding, and the product center keeps approval authority ^77757874.

FDA's February 2026 town hall described an illustrative schedule: a 60-day pre-submission period, a 14 to 21 day filing period, and a 30 to 60 day review ⁷⁸. Vouchers cannot be transferred ⁷⁴⁷⁷. The approval standard does not change, a voucher does not make approval more likely, and FDA can extend the timeline for incomplete data, ambiguous pivotal results, manufacturing problems, or complex reviews ^74757779.

Recipients and outcomes

• Vouchers. FDA named nine recipients on October 16, 2025 and six more on November 6, 2025. With later awards in December, the total reached 18 by December 19, 2025 ^79808183.
• 2026 awards. On April 24, 2026, FDA announced three more vouchers, for psilocybin and methylone programs in depression and PTSD ⁴¹⁴⁴¹⁸.
• Status in April 2026. At the Foundayo approval on April 1, 2026, FDA reported 18 vouchers awarded and six CNPV decisions issued ⁴¹⁶.

Reported approvals under the pilot include:

A voucher does not guarantee approval. Bitopertin was in the first group of recipients, but it received a complete response letter on February 13, 2026, after about four months of review ⁵⁹.

Two points matter when comparing these timelines with PDUFA goals:

• The 1 to 2 month target starts at filing or final submission. The Otarmeni history shows a two-month gap between receipt and filing ³⁸⁰.
• Much of the CMC and labeling review happens during the 60-day pre-submission window ⁷⁷⁷⁸.

Open issues

CNPV has no dedicated statute. FDA's March 23, 2026 Federal Register notice, which announced a public hearing and requested comments, relies on FDA's general authority under the FD&C Act and PHS Act ³²⁷. In January 2026 FDA also issued a staff manual guide describing who makes decisions under the program ⁶⁰. As of March 2026, FDA had issued no guidance document defining the program ³²⁷⁶⁰.

Critics have raised several concerns:

• the lack of explicit statutory authority ^327329331;
• vague selection criteria that mix clinical and industrial-policy goals (onshoring, pricing) ^327331333;
• the risk of political influence on product selection ^327328332;
• diversion of reviewers from non-CNPV applications that are working to PDUFA goals ^328329331;
• less time to work through safety signals and complex data ^327328331.

Practical implications for sponsors

• Choose by development stage. Fast Track is available on nonclinical or mechanistic data and mainly buys access to FDA ²⁸³⁶. BTD and RMAT pay off most when requested before the pivotal trials, because their main value is FDA input on trial design ³⁸³¹⁸⁴.
• Choose RMAT over BTD where eligible. For cell and gene therapies without head-to-head evidence, RMAT gives the same engagement without the substantial-improvement showing ⁸⁵⁸⁴.
• Plan the clock around filing. For NMEs and original BLAs, the priority goal runs 6 months from the 60-day filing date ²⁶⁹. Major amendments can add three months, as Palynziq shows ³⁵¹. Rolling review can shorten the gap between data lock and action, as in Cabometyx ²⁹⁶²⁹⁷.
• Treat designations as revocable. FDA can rescind Fast Track, BTD, and RMAT as the evidence or the treatment landscape changes ^31384132129.
• For CNPV, be submission-ready before you ask. The pilot depends on CMC and labeling being ready 60 days before final submission, and on fast sponsor responses ⁷⁷⁷⁵. Readiness is also a selection criterion ⁷⁵⁷⁸. The bitopertin complete response shows that speed does not substitute for a clean dossier ⁵⁹.